Certain treatments were associated with an increased risk of death unrelated to testicular cancer.
Real-world data validate recently reported findings from clinical trials.
A nurse coordinated a meeting to ensure the patient’s preferences were shared with his multidisciplinary care team.
Accurate kidney function assessment is a crucial consideration when prescribing a patient’s anticancer therapy regimen.
Patients with BCG-unresponsive, non–muscle-invasive bladder cancer who received pembrolizumab had a complete response rate of 41%.